Trial Profile
An investigator-sponsored trial of bemcentinib with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2018
Price :
$35
*
At a glance
- Drugs Bemcentinib (Primary) ; Dabrafenib; Dabrafenib/trametinib; Pembrolizumab; Trametinib
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Mar 2018 Status changed from planning to recruiting, as reported in a BerGenBio media release.
- 15 Feb 2018 New trial record